Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in California: - UCSF at Berkeley Outpatient Center — Berkeley, California
- Alta Bates Summit Medical Center-Herrick Campus Comprehensive Cancer Center — Berkeley, California
- UCSD Medical Center - Encinitas — Encinitas, California
- Palo Alto Medical Foundation - Fremont Center — Fremont, California
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) — La Jolla, California
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in California: - Los Angeles Cancer Network - Anaheim — Anaheim, California
- Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim, California
- Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California
- Kaiser Permanente Bellflower Medical Offices — Bellflower, California
- Kaiser Permanente Fontana Medical Center — Fontana, California
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in California: - Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Cerritos, California
- Clinical Study Site — Corona, California
- Clinical Study Site — Duarte, California
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Mission Hope Medical Oncology - Santa Maria — Santa Maria, California
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in California: - CBCC Global Research — Bakersfield, California
- Los Angeles Cancer Network — Glendale, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA — Santa Monica, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in California: - USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Local Institution - 0330 — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- California Pacific Medical Center - Pacific Campus — San Francisco, California
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in California: - City of Hope — Arcadia, California
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in California: - City of Hope National Medical Center /ID# 279449 — Duarte, California
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in California: - Local Institution - 2129 — Duarte, California
- Local Institution - 2120 — Glendale, California
- Local Institution - 2136 — La Jolla, California
- Local Institution - 2114 — La Jolla, California
- Local Institution - 2121 — Long Beach, California
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sansum Clinic — Santa Barbara, California
- Providence Medical Foundation — Santa Rosa, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Hematology/Oncology- Santa Monica — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in California: - University of California, Los Angeles (UCLA) — Los Angeles, California
- Stanford Cancer Institute, Stanford University — Palo Alto, California
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Sarcoma Oncology Center — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in California: - The Oncology Institute of Hope and Innovation — Cerritos, California
- Ellison Medical Institute — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- University of California Irvine — Orange, California
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Medical Center — Santa Monica, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metasta…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691491
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07659795
Sites in California: - START Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Valkyrie Clinical Trials (contact for more locations) — Los Angeles, California
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in California: - Providence Medical Foundation - Fullerton /ID# 274207 — Fullerton, California
- USC Norris Comprehensive Cancer Center /ID# 274550 — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in California: - UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
- UCLA — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RA…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07397338
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Valkyrie Clinical Trials — Los Angeles, California
- Los Angeles Cancer Network — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in California: - START Los Angeles — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 in…
Sponsor: Pfizer
NCT ID: NCT04557449
Sites in California: - Ellison Institute — Los Angeles, California